X

Trial Profile

A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vociprotafib (Primary)
Indications Carcinoma; Gynaecological cancer; Non-small cell lung cancer; Sarcoma; Solid tumours; Uterine cancer
Focus Adverse reactions; First in man
Sponsors REVOLUTION Medicines

Most Recent Events

31 Aug 2022 Planned End Date changed from 30 Nov 2022 to 31 Mar 2023.
31 Aug 2022 Planned primary completion date changed from 31 Jul 2022 to 31 Mar 2023.
31 Aug 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com